CytomX Therapeutics (NASDAQ:CTMX) had its price objective boosted by Jefferies Group to $40.00 in a report issued on Thursday morning, The Fly reports. Jefferies Group currently has a buy rating on the biotechnology company’s stock.
CTMX has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of CytomX Therapeutics from a hold rating to a sell rating in a research report on Monday, February 5th. Citigroup began coverage on shares of CytomX Therapeutics in a research report on Friday, January 5th. They set a buy rating and a $40.00 price target for the company. Cantor Fitzgerald set a $40.00 price target on shares of CytomX Therapeutics and gave the stock a buy rating in a research report on Thursday. BidaskClub raised shares of CytomX Therapeutics from a buy rating to a strong-buy rating in a research report on Wednesday, February 7th. Finally, ValuEngine downgraded shares of CytomX Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. CytomX Therapeutics has an average rating of Buy and a consensus target price of $35.67.
Shares of CytomX Therapeutics (NASDAQ CTMX) opened at $34.10 on Thursday. CytomX Therapeutics has a 1 year low of $12.51 and a 1 year high of $35.00.
A number of institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors boosted its holdings in CytomX Therapeutics by 39.4% in the second quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 4,622 shares during the period. Iguana Healthcare Management LLC boosted its holdings in CytomX Therapeutics by 7.1% in the fourth quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $1,583,000 after purchasing an additional 5,000 shares during the period. Algert Global LLC boosted its holdings in CytomX Therapeutics by 11.7% in the fourth quarter. Algert Global LLC now owns 51,233 shares of the biotechnology company’s stock worth $1,082,000 after purchasing an additional 5,380 shares during the period. New York State Common Retirement Fund boosted its holdings in CytomX Therapeutics by 18.6% in the third quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 5,800 shares during the period. Finally, Bank of Montreal Can acquired a new position in CytomX Therapeutics in the fourth quarter worth $124,000. 78.50% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3257226/jefferies-group-increases-cytomx-therapeutics-ctmx-price-target-to-40-00.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.